We are pleased to announce the release of our latest sector publication “BELGIAN NUCLEAR MEDICINE”, realised in cooperation with the FPS Foreign Affairs, Foreign Trade and Development Cooperation, Flanders Investment & Trade (FIT), the Wallonia Export & Investment Agency and hub.brussels.
This publication highlights the critical role of nuclear medicine in diagnosing, interpreting, and treating a diverse array of diseases. Nuclear medicine offers patients less invasive treatment alternatives by imaging, treating, and monitoring conditions such as cancer. Despite the pressures on the supply chain, Belgium remains a leading producer of medical isotopes, expertly managing every link of the supply chain. This leadership provides Belgian enterprises unique opportunities to secure their future market position and contribute significantly to global health in an era filled with healthcare challenges.
The first part of this publication offers a detailed overview of nuclear medicine and outlines the supply chain challenges, including nuclear waste and transportation. It also explores how Belgium is addressing these issues to maintain its leading role. The second part includes interviews with 9 innovative Belgian companies active in this sector. The third part introduces various stakeholders in the nuclear medicine field, from sector federations to public institutions that support the industry.
Within the framework of this publication, three Belgian companies have been video interviewed. After PanTera and IBA, a third video interview of Precirix will be published soon. Stay tuned!
